T
trade.cloudexit.ch
Biotech catalyst dashboard · event-driven setup · source-first framing

Trade the window, not the story.

This dashboard turns the biotech catalyst watchlist into a trading-oriented shell. The primary focus stays on INMB and UNCY, while the imported queue keeps the broader screenshot names visible until they earn a fuller catalyst note. The goal is simple: identify what can move next, how near the date window feels, and which names still need source-backed work before sizing anything.

2 primary setupsINMB and UNCY are the only names on this page with explicit catalyst framing.
6 biotech names in queueSMMT, RLAY, ZURA, NUVL, JSPR, and SER remain visible for follow-up research.
1 ETF excludedFLXI stays flagged as non-biotech so the dashboard does not blur single-name catalyst trades with fund exposure.

Biotech Catalyst Dashboard

Built from the biotech catalyst watchlist and reframed for quick triage: what is near-term, what is mid-cycle, and what still needs deeper work before it deserves a trade plan.

Updated: 2026-07-02 08:45 UTC
Near-term focusUNCY remains the clearest date-driven FDA setup on the page.
Narrative sensitivityINMB can move hard on data interpretation and regulatory path updates.
Research queueSix imported biotech names are visible but still underdeveloped.
Discipline ruleKeep FLXI outside biotech catalyst sizing decisions.

Primary focus names

The watchlist starts with the two names that already had explicit catalyst notes: one cleaner FDA date setup, one higher-beta narrative setup.

NASDAQ: INMB

INmune Bio

Small-cap biotech focused on Alzheimer’s disease and an oncology/immunology pipeline.

$1.66 +3.07%
Market cap: $43.3M Volume: 532,190 Bias: narrative + regulatory path

INmune Bio’s current pipeline is centered on XPro1595 in early Alzheimer’s disease, CORDStrom in RDEB, and INKmune in cancer. The trade case is less about a single binary date and more about whether the company keeps validating a registrational path and supplying credible follow-through data.

  • XPro1595: watch final protocol submission timing, management updates, and additional MINDFuL imaging analyses.
  • CORDStrom: company guidance pointed to a UK MHRA filing in mid-summer 2026, EMA filing shortly after, and an FDA BLA submission expected in Q4 2026.
  • INKmune: ongoing Phase 1/2 work in metastatic castration-resistant prostate cancer; monitor for enrollment or data updates, not a near-term approval event.
NASDAQ: UNCY

Unicycive Therapeutics

Biotech with a visible FDA angle centered on oxylanthanum carbonate.

$5.68 +12.58%
Market cap: $125.2M Volume: 5,998,670 Bias: cleaner FDA review setup

Unicycive’s pipeline is straightforward: oxylanthanum carbonate for hyperphosphatemia in CKD patients on dialysis, and UNI-494 for acute-kidney-injury-related conditions. The dashboard keeps UNCY in the front row because OLC remains the clearest near-term value driver.

  • OLC: the company’s May 2026 update gave a PDUFA target action date of June 29, 2026, making this the cleanest catalyst window on the board.
  • If approved, commercial-readiness work was already underway, so the next market reaction could extend beyond the binary event itself.
  • UNI-494: orphan-drug designated for prevention of delayed graft function; the next event to watch is company guidance on the next clinical step.

Catalyst map

Three buckets keep the page honest: active trade setups, approaching regulatory work, and names that still need source-backed homework.

Near-term tradable
UNCY / OLC
Binary-style FDA framing makes it the cleanest event trade on the page.
INMB / XPro1595 updates
More narrative-driven, but still sensitive to protocol and imaging headlines.
Mid-cycle monitors
INMB / CORDStrom
Track filing milestones through MHRA, EMA, and expected FDA BLA sequencing.
UNCY / UNI-494
Monitor the next clinical-step guidance rather than forcing a near-term trade label.
Do not overclaim
Queue first, thesis later
Imported names stay visible, but they do not graduate into focus status until the catalyst is source-backed.
FLXI stays excluded
ETF exposure is not the same thing as a single-name biotech catalyst setup.

Imported queue

These names came over from the broader biotech watchlist. They stay on the dashboard so they are not forgotten, but each still needs a proper source-backed catalyst note.

Queue radar
SMMTImported biotech name from the screenshot queue for future catalyst review.
RLAYImported biotech name from the screenshot queue for future catalyst review.
ZURAImported biotech name from the screenshot queue for future catalyst review.
NUVLImported biotech name from the screenshot queue for future catalyst review.
JSPRImported biotech name from the screenshot queue for future catalyst review.
SERImported biotech name from the screenshot queue for future catalyst review.
Excluded: FLXI is a non-biotech ETF allocation

FDA process cheat sheet

Kept deliberately short so the dashboard still works as a fast trading page: understand where the company is in the path, then decide whether the event is actually near enough to trade.

Phase 1
  • Early safety, dose finding, tolerability.
  • Usually too early for clean approval-date framing.
Phase 2 / 2b
  • Proof-of-concept and dose refinement.
  • Often where narrative sensitivity starts to matter.
Phase 3 / NDA / BLA
  • Registrational path, filing, review, and action date.
  • This is where cleaner binary catalyst setups usually appear.

Source links

The page stays source-first on purpose. Use market pages for quick quote context and FDA/company materials for event validation.

Market pages
Official FDA references